Focus: Mammoth Biosciences is a CRISPR and gene-editing therapeutics company founded in 2024, currently in very early stage with minimal commercial footprint. The company is headquartered in Brisbane, CA and focused on developing gene therapy solutions.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
High-risk, high-reward pre-revenue biotech requiring conviction in founding team and CRISPR IP; suitable only for early-stage-motivated talent comfortable with binary outcomes.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Mammoth Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Mammoth Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: BridgeBio Pharma, Inc. (BBIO) (CIK 0001743881) — EXHIBIT 99.1
EXHIBIT 99.1
Abu Dhabi partners with US biotech firm to advance gene-editing therapies - Gulf News
Abu Dhabi partners with US biotech firm to advance gene-editing therapies Gulf News
Intellia's In Vivo CRISPR Drug Slashes Swelling Attacks in Phase III HAE Trial - Precision Medicine Online
Intellia's In Vivo CRISPR Drug Slashes Swelling Attacks in Phase III HAE Trial Precision Medicine Online
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy.
Existence of Causation without Correlation in Transcriptional Networks.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo